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oncologists to conﬁrm if the literature descriptions of 
the modalities were consistent with experience in clinical
practice. Draft descriptions were then prepared, and crit-
ically reviewed by patients from each of the treatment
modalities for not only accuracy and relevance but 
also comprehensibility. Patients were also speciﬁcally
instructed in these qualitative interviews to describe the
impact of their treatment modalities on their everyday
lives, to ensure that the ensuing descriptions captured rel-
evant patient outcomes and were phrased in language
used by patients. Finally, interviews were carried out 
with lay persons to review the descriptions for clarity and
comprehensibility.
RESULTS: The three commonly used treatment modali-
ties for CRC were Modiﬁed de Gramont, Mayo, and
Xeloda. It was decided to describe each modality in terms
of efﬁcacy, adverse events, administration procedures,
and patient outcomes. For ease of comprehension, pa-
tients and lay persons suggested presenting the informa-
tion in separate sections. Subjects were satisﬁed that the
ensuing descriptions accurately captured the relevant
issues and were comprehensible.
CONCLUSION: We have successfully prepared accurate
and comprehensible descriptions of treatment modalities
and ensuing health states in CRC. These descriptions may
be useful in health state preference measurement studies
using non-patients as respondents.
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Reimbursement and other health policy decisions may be
highly inﬂuenced by analysis of claim-based utilization.
Secondary analyses of medical claims data to describe
patterns of resource utilization often rely on arbitrarily
deﬁned timeframes. In oncology, where treatment is in
short deﬁned time periods, both simple use-per-time 
averaging and illness-episode approaches based on
primary diagnosis and treatment may inaccurately esti-
mate resource utilization.
OBJECTIVE: This study examined the variation in uti-
lization of an injectable oncology supportive care agent
using three different analytical techniques.
METHODS: Patients with a principal diagnosis of cancer
and use of ﬁlgrastim were extracted from the 1996–98
Medicare 5% claims database. Patterns of resource 
utilization were compared with 1) simple use-per-time 
averaging; 2) illness-episode aggregation; and 3) per-
chemotherapy cycle aggregation. Descriptive statistics for
the number of days of utilization are reported.
RESULTS: A total of 5,160 patients yielding 2.9 million
claims were analyzed. The range of ﬁlgrastim resource
utilization varied considerably depending on the analysis
technique used: simple use-per-time was 1 to 159 days;
illness-episode aggregation was 1 to 51 days; and per-
chemotherapy cycle aggregation was 1 to 15 days. For all
analyses, the medical claims data do not provide adequate
rationale for use or days of utilization, and therefore this
database has limited value as a guide to future decision-
making. In addition, the analysis was limited in the ability
to accurately identify chemotherapy regimens; differenti-
ate prophylactic vs. treatment use of supportive agents;
and in describing oral chemotherapy use, dose delays and
reductions, and reasons for chemotherapy alterations.
CONCLUSION: Resource utilization in oncology is
highly inﬂuenced by the data source and the analysis
method chosen, which may not allow for an accurate
understanding of practice patterns. Only by understand-
ing these limitations in speciﬁc disease areas can the
medical decision-making be improved leading to better
patient outcomes.
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Prevalence of peripheral arterial disease (PAD) has been
constantly grown over the past decades. However, in-
consistent data on PAD prevalence from published liter-
ature were limited in use for either research or disease
management.
OBJECTIVES: The purposes of this review were to sum-
marize published PAD prevalence and to identify factors
that may cause the variation in PAD prevalence.
METHODS: English-language studies published between
1980 to December 2001 were identiﬁed through a
MEDLINE search.
RESULTS: Thirty-one studies on PAD prevalence were
identiﬁed. The present review showed that the prevalence
of PAD varied and it was highly dependent on the deﬁn-
ition of clinical presentations. Additional factors for the
variation included type, sensitivity and/or speciﬁcity of
diagnostic tests for screening and the distribution of risks
for PAD including age, male gender, smoking, diabetes
and dyslipidemia. The review showed that the prevalence
of PAD varied ranging from 1.2% in general population
to 29% in high-risk patients. After adjusting for age,
gender and clinical presentation, the overall PAD preva-
lence and the prevalence with intermittent claudication
were 8.7% to 26.5% and 1.6% to 2.9% respectively.
Prevalence of PAD was often higher (2 to 7 times) in
studies using a combination of noninvasive tests, patient
reported history and physical examinations for diagnosis
than that in those studies using only patient history plus
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physical examinations. Under-diagnosis for PAD in prac-
tice was common and it might have under-estimated PAD
prevalence.
CONCLUSIONS: Previously reported PAD prevalence
varies depending on clinical presentations, different
screening tools, and the distribution of risks for PAD.
Understanding of and effectively adjusting for these
factors may be helpful to appropriately interpret and
utilize the study results for future research.
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OBJECTIVES: Recent analyses suggest that pulse pres-
sure is an important and independent risk factor for car-
diovascular disease. Accordingly, pulse pressure may also
be an important variable for inclusion in economic analy-
ses of hypertension therapy. We therefore analyzed the
relationship between pulse pressure and cardiovascular
events after adjustment for other risk factors to determine
if pulse pressure is an explanatory variable in the treat-
ment of hypertension. We then evaluated the importance
of pulse pressure as an explanatory variable in the treat-
ment of hypertension.
METHODS: Using multivariate analyses and data from
the Lipid Research Clinic Cohort, we examined the asso-
ciation between speciﬁc blood pressure measures and car-
diovascular death after adjustment for age and other risk
factors. We then compared the goodness of ﬁt (GOF =
[observed events–expected events]2) of various Markov
models to forecast the results of randomized clinical trials
of hypertension therapy using single blood measures or
combinations of measures.
RESULTS: Pulse pressure is a strong univariate risk factor
for coronary and cardiovascular death. Both pulse pres-
sure and diastolic blood pressure were independent (p <
0.05) risk factors with a signiﬁcant negative interaction
between increasing age and diastolic blood pressure and
a positive but non-signiﬁcant pulse pressure x age inter-
action. In Markov model simulations, the model in-
cluding diastolic and pulse pressure better approximated
(GOF = 91) the observed outcomes in ﬁve clinical trials
compared to either systolic, diastolic or pulse pressure
alone (GOF = 208, 375, 706 respectively).
CONCLUSION: Pulse pressure is a signiﬁcant indepen-
dent risk factor for cardiovascular events that increases
in relative importance with increasing age. When pulse
pressure is added to a Markov model with diastolic blood
pressure the results of clinical trials are more accurately
forecasted. Economic analyses of hypertension therapy
may be enhanced by considering blood pressure changes
other than only systolic or diastolic in isolation.
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OBJECTIVES: Cost of treatment for patients with the
same diagnosis can vary enormously due to differences in
comorbidities, practice patterns, and outcomes of care.
We sought to incorporate this variability in a model pro-
jecting the results of clinical trials to community practice.
METHODS: We modeled an episode of care for persons
hospitalized due to acute decompensated heart failure and
urgently treated with either nesiritide or dobutamine.
Patient characteristics and probability of signiﬁcant 
clinical events (cardiac arrest, sustained and non-
sustained ventricular tachycardia, hypotension, vomiting,
readmission and death during follow-up) were based on
pooled analysis of two completed clinical trials. The cost
of a hospital admission was derived from a subset of
records from the 1997 HCUP hospital database for dis-
charges with similar demographic and clinical features (n
= 57,223). Regressions were estimated for equations
explaining 1) hospital length of stay as a function of
patient attributes and speciﬁed clinical events; 2) the cost
of the admission as a function of patient attributes, clin-
ical events and predicted length of stay (LOS). For each
of 5000 simulated patients, the model ﬁrst stochastically
generates new sets of regression parameters using the
means and standard deviations of the original parameter
estimates. Next the model predicts patient demographic
characteristics and incidence of clinical events. The vector
of patient attributes is applied to the vectors of regression
parameters to predict LOS and then cost as a function of
predicted LOS.
RESULTS: This approach preserved distributional char-
acteristics of the original HCUP data (e.g. model pre-
dicted cost of admission vs. HCUP: mean 14,807 vs.
14,666; skew 2.94 vs. 3.16; kurtosis 10.03 vs. 11.43)
while enabling us to differentiate study drugs based on
incidence of clinical events.
CONCLUSIONS: The model yields robust estimates of
cost. Conﬁdence intervals surrounding point estimates
offer decision-makers a reliable basis for assessing 
potential ﬁnancial impact and uncertainty surrounding
adoption of the treatment intervention.
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